ロード中...
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Pembrolizumab monotherapy has been approved for the first- and second-line treatment of patients with PD-L1-expressing advanced non-small cell lung cancer (NSCLC). Testing for PD-L1 expression with the PD-L1 immunohistochemistry (IHC) 22C3 companion diagnostic assay, which gives a tumor proportion s...
保存先:
| 出版年: | J Vis Exp |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MyJove Corporation
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6235290/ https://ncbi.nlm.nih.gov/pubmed/30320751 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3791/58082 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|